Hyaluronidase induces murine L929 fibrosarcoma cells resistant to tumor necrosis factor and Fas cytotoxicity in the presence of actinomycin D

Cell Biochem Biophys. 1995;27(2):109-32. doi: 10.1007/BF02815401.

Abstract

Actinomycin D (ActD) enhances the potency of tumor necrosis factor-alpha (TNF-alpha) in killing cancer cells. However, it is determined in this study that murine L929 fibrosarcoma cells, when pretreated with bovine testicular hyaluronidase for 12-24 h, became resistant to the cytotoxic effect of TNF-alpha in the presence of DNA intercalators, such as ActD, doxorubicin, and daunorubicin. Monoclonal anti-Fas antibody-mediated apoptosis in the presence of ActD was also blocked in hyaluronidase-pretreated L929 cells. Hyaluronidase failed to up- or downregulate the expression of apoptosis regulatory proteins, including Bcl-2, Bcl-xL, ICH-1, and TIAR, suggesting that these proteins were not involved in the hyaluronidase-induced resistance to TNF/ActD. A semisynthetic polysulfated hyaluronic acid (HA) inhibited the increased TNF/ActD resistance, whereas unmodified HA, dextran sulfate, and naturally polysulfated glycosaminoglycans had no effect. Evidence is provided here that the induced resistance is related to serum fetuin and a novel intracellular 35-kDa TNF-binding protein (intra TBP). Under serum-free conditions, L929 became refractory to TNF/ActD cytotoxicity and hyaluronidase reversed the resistance. Exogenous fetuin increased L929 cell spreading and proliferation, and restored hyaluronidase-induction of TNF/ActD resistance in these serum-starved cells. Hyaluronidase failed to reduce the expression of TNF-receptors and their binding of TNF-alpha. However, binding and Western-blotting analyses revealed that hyaluronidase downregulated the intra-TBP. Overall, these observations suggest that serum fetuin and intraTBP are involved in the hyaluronidase induction of TNF/ ActD resistance.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / pharmacology*
  • Apoptosis / drug effects
  • Carrier Proteins / metabolism
  • Cattle
  • Cell Division / drug effects
  • Cycloheximide / pharmacology
  • DNA Damage
  • Dactinomycin / pharmacology*
  • Daunorubicin / pharmacology
  • Down-Regulation / drug effects
  • Doxorubicin / pharmacology
  • Drug Resistance, Neoplasm
  • Fibrosarcoma / drug therapy*
  • Hyaluronoglucosaminidase / antagonists & inhibitors
  • Hyaluronoglucosaminidase / pharmacology*
  • Male
  • Mice
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-bcl-2 / metabolism
  • RNA-Binding Proteins / metabolism
  • Receptors, Tumor Necrosis Factor*
  • Receptors, Tumor Necrosis Factor, Type I
  • Testis / enzymology
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor Decoy Receptors
  • Tumor Necrosis Factor-alpha / pharmacology*
  • alpha-Fetoproteins / pharmacology
  • bcl-X Protein
  • fas Receptor / immunology*

Substances

  • Antibiotics, Antineoplastic
  • Bcl2l1 protein, mouse
  • Carrier Proteins
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • RNA-Binding Proteins
  • Receptors, Tumor Necrosis Factor
  • Receptors, Tumor Necrosis Factor, Type I
  • Tial1 protein, mouse
  • Tumor Necrosis Factor Decoy Receptors
  • Tumor Necrosis Factor-alpha
  • alpha-Fetoproteins
  • bcl-X Protein
  • fas Receptor
  • Dactinomycin
  • recombinant human tumor necrosis factor-binding protein-1
  • Doxorubicin
  • Cycloheximide
  • Hyaluronoglucosaminidase
  • Daunorubicin